date: 2018-10-20T08:32:30Z
pdf:PDFVersion: 1.5
pdf:docinfo:title: Pazopanib, Cabozantinib, and Vandetanib in the Treatment of Progressive Medullary Thyroid Cancer with a Special Focus on the Adverse Effects on Hypertension
xmp:CreatorTool: LaTeX with hyperref package
access_permission:can_print_degraded: true
subject: Medullary thyroid cancer (MTC) is a rare malignancy with a poor prognosis. First line therapy is surgery, which is the only curative method of the disease. However, in non-operable cases or with tumor progression and metastases, a systemic treatment is necessary. This form of cancer is often insensitive to conventional chemotherapy, but the use of tyrosine kinase inhibitors (TKIs), such as pazopanib, cabozantinib, and vandetanib, has shown promising results with an increase in progression-free survival and prolonged lifetime. Therefore, we focused on the pharmacological characteristics of TKIs, their mechanism of action, their application as a secondary treatment option for MTC, their efficacy as a cancer drug treatment, and reviewed the ongoing clinical trials. TKIs also act systemically causing various adverse events (AEs). One common AE of this treatment is hypertension, known to be associated with cardiovascular disease and can therefore potentially worsen the well-being of the treated patients. The available treatment strategies of drug-induced hypertension were discussed. The mechanism behind the development of hypertension is still unclear. Therefore, the treatment of this AE remains symptomatic. Thus, future studies are necessary to investigate the link between tumor growth inhibition and hypertension. In addition, optimized, individual treatment strategies should be implemented.
dc:format: application/pdf; version=1.5
pdf:docinfo:creator_tool: LaTeX with hyperref package
access_permission:fill_in_form: true
pdf:encrypted: false
dc:title: Pazopanib, Cabozantinib, and Vandetanib in the Treatment of Progressive Medullary Thyroid Cancer with a Special Focus on the Adverse Effects on Hypertension
modified: 2018-10-20T08:32:30Z
cp:subject: Medullary thyroid cancer (MTC) is a rare malignancy with a poor prognosis. First line therapy is surgery, which is the only curative method of the disease. However, in non-operable cases or with tumor progression and metastases, a systemic treatment is necessary. This form of cancer is often insensitive to conventional chemotherapy, but the use of tyrosine kinase inhibitors (TKIs), such as pazopanib, cabozantinib, and vandetanib, has shown promising results with an increase in progression-free survival and prolonged lifetime. Therefore, we focused on the pharmacological characteristics of TKIs, their mechanism of action, their application as a secondary treatment option for MTC, their efficacy as a cancer drug treatment, and reviewed the ongoing clinical trials. TKIs also act systemically causing various adverse events (AEs). One common AE of this treatment is hypertension, known to be associated with cardiovascular disease and can therefore potentially worsen the well-being of the treated patients. The available treatment strategies of drug-induced hypertension were discussed. The mechanism behind the development of hypertension is still unclear. Therefore, the treatment of this AE remains symptomatic. Thus, future studies are necessary to investigate the link between tumor growth inhibition and hypertension. In addition, optimized, individual treatment strategies should be implemented.
pdf:docinfo:subject: Medullary thyroid cancer (MTC) is a rare malignancy with a poor prognosis. First line therapy is surgery, which is the only curative method of the disease. However, in non-operable cases or with tumor progression and metastases, a systemic treatment is necessary. This form of cancer is often insensitive to conventional chemotherapy, but the use of tyrosine kinase inhibitors (TKIs), such as pazopanib, cabozantinib, and vandetanib, has shown promising results with an increase in progression-free survival and prolonged lifetime. Therefore, we focused on the pharmacological characteristics of TKIs, their mechanism of action, their application as a secondary treatment option for MTC, their efficacy as a cancer drug treatment, and reviewed the ongoing clinical trials. TKIs also act systemically causing various adverse events (AEs). One common AE of this treatment is hypertension, known to be associated with cardiovascular disease and can therefore potentially worsen the well-being of the treated patients. The available treatment strategies of drug-induced hypertension were discussed. The mechanism behind the development of hypertension is still unclear. Therefore, the treatment of this AE remains symptomatic. Thus, future studies are necessary to investigate the link between tumor growth inhibition and hypertension. In addition, optimized, individual treatment strategies should be implemented.
pdf:docinfo:creator: Rikke Vilsbřll Milling, Daniela Grimm, Marcus Krüger, Jirka Grosse, Sascha Kopp, Johann Bauer, Manfred Infanger and Markus Wehland
PTEX.Fullbanner: This is pdfTeX, Version 3.14159265-2.6-1.40.18 (TeX Live 2017/W32TeX) kpathsea version 6.2.3
meta:author: Rikke Vilsbřll Milling, Daniela Grimm, Marcus Krüger, Jirka Grosse, Sascha Kopp, Johann Bauer, Manfred Infanger and Markus Wehland
trapped: False
meta:creation-date: 2018-10-20T08:32:30Z
created: 2018-10-20T08:32:30Z
access_permission:extract_for_accessibility: true
Creation-Date: 2018-10-20T08:32:30Z
Author: Rikke Vilsbřll Milling, Daniela Grimm, Marcus Krüger, Jirka Grosse, Sascha Kopp, Johann Bauer, Manfred Infanger and Markus Wehland
producer: pdfTeX-1.40.18
pdf:docinfo:producer: pdfTeX-1.40.18
pdf:unmappedUnicodeCharsPerPage: 17
Keywords: medullary thyroid carcinoma; hypertension; VEGF; antiangiogenesis; tyrosine kinase inhibitors
access_permission:modify_annotations: true
dc:creator: Rikke Vilsbřll Milling, Daniela Grimm, Marcus Krüger, Jirka Grosse, Sascha Kopp, Johann Bauer, Manfred Infanger and Markus Wehland
dcterms:created: 2018-10-20T08:32:30Z
Last-Modified: 2018-10-20T08:32:30Z
dcterms:modified: 2018-10-20T08:32:30Z
title: Pazopanib, Cabozantinib, and Vandetanib in the Treatment of Progressive Medullary Thyroid Cancer with a Special Focus on the Adverse Effects on Hypertension
Last-Save-Date: 2018-10-20T08:32:30Z
pdf:docinfo:keywords: medullary thyroid carcinoma; hypertension; VEGF; antiangiogenesis; tyrosine kinase inhibitors
pdf:docinfo:modified: 2018-10-20T08:32:30Z
meta:save-date: 2018-10-20T08:32:30Z
pdf:docinfo:custom:PTEX.Fullbanner: This is pdfTeX, Version 3.14159265-2.6-1.40.18 (TeX Live 2017/W32TeX) kpathsea version 6.2.3
Content-Type: application/pdf
X-Parsed-By: org.apache.tika.parser.DefaultParser
creator: Rikke Vilsbřll Milling, Daniela Grimm, Marcus Krüger, Jirka Grosse, Sascha Kopp, Johann Bauer, Manfred Infanger and Markus Wehland
dc:subject: medullary thyroid carcinoma; hypertension; VEGF; antiangiogenesis; tyrosine kinase inhibitors
access_permission:assemble_document: true
xmpTPg:NPages: 15
pdf:charsPerPage: 2951
access_permission:extract_content: true
access_permission:can_print: true
pdf:docinfo:trapped: False
meta:keyword: medullary thyroid carcinoma; hypertension; VEGF; antiangiogenesis; tyrosine kinase inhibitors
access_permission:can_modify: true
pdf:docinfo:created: 2018-10-20T08:32:30Z